Dennis Fenton joined Cirius’ board of directors since December 2017. Dr. Fenton has served on the board of directors of Sienna Biopharmaceuticals, Inc. since October 2016. From 1982 until his retirement in 2008, Dr. Fenton worked at Amgen, where he held positions of increasing responsibility, including vice president of research, senior vice president of sales and marketing, senior vice president of operations and executive vice president. Previously, Dr. Fenton worked as a researcher at Pfizer Central in new product development from 1977 to 1981. Dr. Fenton is currently an independent consultant and a member of the board of directors of Portola Pharmaceuticals, Inc., a public pharmaceutical company, Omniox, Inc., a biotechnology company and Modern Meadow, Inc. a private company. Dr. Fenton previously served on the board of directors of then-public life sciences companies Kythera Biopharmaceuticals, Inc., Hospira Inc., Dendreon Corp., Pfenex Inc., Xenoport, Inc. and Genzyme Corporation. He is also a member of the board of trustees of the Keck Graduate Institute. Dr. Fenton received a Ph.D. in microbiology from Rutgers University and a B.S. in biology from Manhattan College.